Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Oligonucleotides as therapeutic agents.

J S Cohen1

  • 1Pharmacology Department, Georgetown University Medical School, Washington DC.

Pharmacology & Therapeutics
|November 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The incremental risk of fragility fractures in aging men.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2023
Same author

De novo variants in KLF7 are a potential novel cause of developmental delay/intellectual disability, neuromuscular and psychiatric symptoms.

Clinical genetics·2017
Same author

Expansion and further delineation of the SETD5 phenotype leading to global developmental delay, variable dysmorphic features, and reduced penetrance.

Clinical genetics·2017
Same author

Further evidence that de novo missense and truncating variants in ZBTB18 cause intellectual disability with variable features.

Clinical genetics·2016
Same author

Depression among adults with neurofibromatosis type 1: prevalence and impact on quality of life.

Clinical genetics·2014
Same author

The role of trial tracking on rats' successive delayed matching-to-sample modality performance.

Behavioural processes·2014

Chemically modified oligodeoxynucleotides offer a practical approach to regulating gene expression. These "informational drugs" can selectively target viral and cellular genes, though some exhibit non-specific polymerase inhibition.

Area of Science:

  • Molecular Biology
  • Antisense Technology
  • Drug Discovery

Background:

  • Oligodeoxynucleotides function as antisense agents by binding to mRNA targets.
  • Chemical modifications enhance nuclease resistance, enabling practical antisense strategies.
  • Understanding cellular uptake and gene regulation is crucial for therapeutic applications.

Purpose of the Study:

  • To describe studies on oligodeoxynucleotide analogs in cell-free and cellular systems.
  • To investigate the gene regulatory effects of modified oligodeoxynucleotides.
  • To explore potential non-specific inhibitory mechanisms.

Main Methods:

  • In vitro studies using cell-free systems.
  • Assessment of cellular uptake of oligodeoxynucleotide analogs.

Related Experiment Videos

  • Analysis of viral and cellular gene expression regulation.
  • Investigation of polymerase inhibition by oligodeoxynucleotide analogs.

    • Main Results:

    • Modified oligodeoxynucleotides demonstrate nuclease resistance for practical use.
    • Certain analogs effectively regulate viral and cellular gene expression.
    • Non-specific inhibition was observed, linked to polymerase interactions.

    Conclusions:

    • Chemically modified oligodeoxynucleotides are viable tools for gene expression regulation.
    • These analogs can be considered 'informational drugs' with therapeutic potential.
    • Further research is needed to mitigate non-specific effects and optimize targeting.